Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Representative image of oncology researchers analysing cancer imaging and laboratory data as SalubrisBio’s JK06 antibody drug conjugate shows early Phase 1/2 promise in 5T4-targeted treatment for lung cancer and breast cancer.
Pharma & Biotech

SalubrisBio’s JK06 shows early promise, but can 5T4 ADCs move beyond niche excitement?

Find out how SalubrisBio’s JK06 data could reshape 5T4-targeted ADC development in lung and breast cancer.

Read More
Representative image of an oncology consultation for advanced prostate cancer treatment, as Bayer’s NUBEQA cognitive decline data from the ARACOG trial raises new questions about quality-of-life differences between darolutamide and enzalutamide.
Pharma & Biotech

Could Bayer’s NUBEQA gain a quality-of-life edge after ARACOG cognitive data?

Find out how Bayer’s NUBEQA cognitive data from ARACOG could reshape prostate cancer treatment choices after ASCO 2026.

Read More
Medical Devices & Diagnostics

Can Veracyte’s Decipher Prostate test change who gets chemotherapy in metastatic prostate cancer?

Can Veracyte’s Decipher Prostate test change chemotherapy decisions in metastatic prostate cancer? Find out what ENZAMET data means today.

Read More
Pharma & Biotech

Pfizer’s prostate cancer combination delivers strong rPFS signal in TALAPRO-3

Talzenna plus Xtandi improved rPFS in HRR-mutated metastatic prostate cancer. Find out what TALAPRO-3 could change next.

Read More
Pharma & Biotech

TUNE-401 gives Tune Therapeutics an early signal in the race for finite HBV therapy

Find out how Tune Therapeutics’ TUNE-401 data could reshape the chronic hepatitis B cure race and what risks remain for Phase 2.

Read More
Representative image of oncology researchers reviewing tumor imaging and clinical trial data, reflecting Immunome’s Phase 3 RINGSIDE results for varegacestat in adults with progressing desmoid tumors.
Pharma & Biotech

Why Immunome’s RINGSIDE data may reset expectations in desmoid tumor treatment

Discover how Immunome’s Phase 3 RINGSIDE data could reshape desmoid tumor treatment and gamma secretase inhibitor competition.

Read More
Representative image: An oncologist reviews lymphoma scan data in a clinical setting as Incyte’s tafasitamab combination shows improved progression-free survival in high-risk diffuse large B-cell lymphoma, raising new questions about the future of first-line DLBCL treatment.
Pharma & Biotech

Incyte’s frontMIND data put pressure on decades-old R-CHOP dominance in high-risk DLBCL

Find out how Incyte’s tafasitamab data could reshape first-line treatment expectations in high-risk DLBCL.

Read More
Representative image of oncology researchers studying tumor biology in a modern laboratory, reflecting Exelixis’ CABINET trial data on CABOMETYX and its potential role in advanced neuroendocrine tumor treatment.
Pharma & Biotech

Can Exelixis defend its oncology franchise with deeper CABINET evidence?

Read how Exelixis’ CABINET subgroup data could sharpen cabozantinib’s role in advanced neuroendocrine tumor care.

Read More
Representative image of an oncologist and clinical care team reviewing AI-powered cancer trial data, reflecting Massive Bio’s Reticulum Nexus push to improve oncology trial matching, biomarker reassessment and patient access after its ASCO 2026 product suite announcement.
Pharma & Biotech

How Massive Bio’s Reticulum Nexus suite is targeting the hidden bottlenecks in cancer trials

Can Massive Bio’s Reticulum Nexus suite close oncology trial access gaps? Find out how AI agents may reshape cancer trial navigation today!

Read More
Representative image of a hepatology researcher reviewing rare liver disease clinical data, reflecting Mirum Pharmaceuticals’ EASL 2026 updates on volixibat, brelovitug and maralixibat across PSC, HDV and PFIC programs.
Pharma & Biotech

Can volixibat and brelovitug expand Mirum Pharmaceuticals’ rare liver disease ambitions?

Mirum Pharmaceuticals’ EASL 2026 data deepen its rare liver disease strategy. Find out what changes for PSC, HDV and PFIC care.

Read More